Systemic Treatment for Advanced HCC: Can Sorafenib Improve PFS/ORR vs. Lenvatinib in Unresectable Disease? Is There OS Benefit With Regorafenib After Sorafenib? | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

The Asian Oncology Society 1st Virtual International Conference

Systemic Treatment for Advanced HCC: Can Sorafenib Improve PFS/ORR vs. Lenvatinib in Unresectable Disease? Is There OS Benefit With Regorafenib After Sorafenib?

By The Asian Oncology Society 1st Virtual International Conference FEATURING Minsig Choi

By The Asian Oncology Society 1st Virtual International Conference FEATURING Minsig Choi

332 views

February 22, 2021

Comments 0

Login to view comments. Click here to Login